These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
340 related articles for article (PubMed ID: 16540725)
21. [Rituximab resistance in B-cell lymphoma and its elimination]. Hatake K; Terui Y Gan To Kagaku Ryoho; 2009 Apr; 36(4):548-51. PubMed ID: 19381025 [TBL] [Abstract][Full Text] [Related]
22. Cutaneous B-cell lymphoma with loss of CD20 immunoreactivity after rituximab therapy. Clarke LE; Bayerl MG; Ehmann WC; Helm KF J Cutan Pathol; 2003 Aug; 30(7):459-62. PubMed ID: 12859745 [TBL] [Abstract][Full Text] [Related]
23. HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells. Shimizu R; Kikuchi J; Wada T; Ozawa K; Kano Y; Furukawa Y Leukemia; 2010 Oct; 24(10):1760-8. PubMed ID: 20686505 [TBL] [Abstract][Full Text] [Related]
24. Recurrent B-cell neoplasms after Rituximab therapy: an immunophenotypic and genotypic study. Chu PG; Chen YY; Molina A; Arber DA; Weiss LM Leuk Lymphoma; 2002 Dec; 43(12):2335-41. PubMed ID: 12613521 [TBL] [Abstract][Full Text] [Related]
25. Predictive significance of the cut-off value of CD20 expression in patients with B-cell lymphoma. Horvat M; Kloboves Prevodnik V; Lavrencak J; Jezersek Novakovic B Oncol Rep; 2010 Oct; 24(4):1101-7. PubMed ID: 20811695 [TBL] [Abstract][Full Text] [Related]
26. Complete remission of a primary cutaneous B-cell lymphoma of the lower leg by first-line monotherapy with the CD20-antibody rituximab. Bonnekoh B; Schulz M; Franke I; Gollnick H J Cancer Res Clin Oncol; 2002 Mar; 128(3):161-6. PubMed ID: 11935303 [TBL] [Abstract][Full Text] [Related]
27. Induction of apoptosis and effect on CD20+ using rituximab on autologous peripheral blood stem cell harvests from patients with B cell lymphomas. Borbolla-Escoboza JR; Leon MI; Collados MT; Baez E; Baltasar S; Hernández R; Rojas JC Stem Cells Dev; 2004 Apr; 13(2):193-6. PubMed ID: 15186735 [TBL] [Abstract][Full Text] [Related]
28. The therapeutic use of rituximab in non-Hodgkin's lymphoma. Marcus R; Hagenbeek A Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982 [TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical CD20-negative change in B-cell non-Hodgkin lymphomas after rituximab-containing therapy. Maeshima AM; Taniguchi H; Fujino T; Saito Y; Ito Y; Hatta S; Yuda S; Makita S; Fukuhara S; Munakata W; Suzuki T; Maruyama D; Izutsu K Ann Hematol; 2020 Sep; 99(9):2141-2148. PubMed ID: 32451711 [TBL] [Abstract][Full Text] [Related]
30. Treatment of radiation-relapsing primary cutaneous B-cell lymphoma with an anti-CD20 monoclonal antibody. Lacouture ME; Baron JM; Jani AB; Laumann AE; Soltani K Clin Exp Dermatol; 2005 Jan; 30(1):46-8. PubMed ID: 15663503 [TBL] [Abstract][Full Text] [Related]
31. Treatment of primary cutaneous follicular centre lymphoma with rituximab: a report of two cases. Kennedy GA; Blum R; McCormack C; Prince HM Australas J Dermatol; 2004 Feb; 45(1):34-7. PubMed ID: 14961906 [TBL] [Abstract][Full Text] [Related]
32. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. Treon SP; Mitsiades C; Mitsiades N; Young G; Doss D; Schlossman R; Anderson KC J Immunother; 2001; 24(3):263-71. PubMed ID: 11394505 [TBL] [Abstract][Full Text] [Related]
33. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Milpied N; Vasseur B; Parquet N; Garnier JL; Antoine C; Quartier P; Carret AS; Bouscary D; Faye A; Bourbigot B; Reguerre Y; Stoppa AM; Bourquard P; Hurault de Ligny B; Dubief F; Mathieu-Boue A; Leblond V Ann Oncol; 2000; 11 Suppl 1():113-6. PubMed ID: 10707791 [TBL] [Abstract][Full Text] [Related]
34. [Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail]. Lin TY; Zhang HY; Huang Y; Guan ZZ; Shen T; Shi YK; Zhu J; Ke XY; Wang HQ; Shen ZX; Yu SY; Liu T; Shi XL Ai Zheng; 2005 Dec; 24(12):1421-6. PubMed ID: 16351785 [TBL] [Abstract][Full Text] [Related]
35. [Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells]. Shi YX; Zhang XS; Xia JC; Li YQ; Xu RH; Han WJ; Zhang JH; Guan ZZ; Jiang WQ Ai Zheng; 2007 Aug; 26(8):837-42. PubMed ID: 17697543 [TBL] [Abstract][Full Text] [Related]
36. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma. Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647 [TBL] [Abstract][Full Text] [Related]